Table 1.
Comparison of Baseline Parameters in Patients in Carvedilol (n = 25) and Propranolol (n = 23) Group Along with Statistical Significance.
| Variable | Carvedilol group (n = 25) | Propranolol group (n = 23) | P value |
|---|---|---|---|
| Age | 41.52 ± 12.54 | 46.7 ± 10.24 | 0.126 |
| Females | 1 (4%) | 4 (17.39%) | 0.180 |
| Etiology | 0.386 | ||
|
1 (4%) | 2 (8.7%) | |
|
7 (28%) | 4 (17.39%) | |
|
14 (56%) | 14 (60.87%) | |
|
2 (8%) | 0 (0%) | |
|
1 (4%) | 3 (13.04%) | |
| Ascites | 16 (64%) | 16 (69.57%) | 0.13 |
| Grade of ascites | 0.503 | ||
|
12 (48%) | 10 (43.48%) | |
|
4 (16%) | 4 (17.39%) | |
|
0 (0%) | 2 (8.7%) | |
| HE | 0 | 0 | – |
| AKI | 0 | 0 | – |
| SBP | 0 (0%) | 1 (4.35%) | 0.479 |
| Drug dose | 6.25 (6.25–12.5) | 40 (40–80) | – |
| HVPG | |||
| Baseline | 17.56 ± 3.14 | 17 ± 2.63 | 0.508 |
| At 4 weeks | 12.72 ± 3.76 | 13.43 ± 3.07 | 0.477 |
| HVPG Response | 18 (72%) | 11 (47.83%) | 0.047 |
| Hemoglobin (g/dl) (mean±SD) | 8.92 ± 1.53 | 10.27 ± 2.23 | 0.02 |
| Platelet count (/mm3) | 72,000 (56,000–100,000) | 99,000 (55,000–155,000) | 0.252 |
| Bilirubin (mg/dl) | 1.5 (0.8–2.8) | 2 (1.7–3.2) | 0.12 |
| AST (IU/L) | 55 (36–87) | 60 (48–102) | 0.353 |
| ALT (IU/L) | 50 (36–78) | 48 (28–75) | 0.804 |
| ALP (IU/L) | 253.44 ± 70.23 | 313 ± 150.2 | 0.081 |
| Creatinine (mg/dl) | 0.85 ± 0.16 | 0.84 ± 0.18 | 0.792 |
| Albumin (g/dl) | 3.54 ± 0.45 | 3.26 ± 0.61 | 0.076 |
| INR | 1.27 ± 0.18 | 1.25 ± 0.23 | 0.736 |
| MELD | 11.36 ± 3.73 | 12 ± 3.34 | 0.536 |
| CTP score | 7 (6–7) | 7 (7–9) | 0.079 |
| Child status | 0.182 | ||
|
9 (36%) | 3 (13.04%) | |
|
14 (56%) | 17 (73.91%) | |
|
2 (8%) | 3 (13.04%) | |
Data are presented as median (IQR) for quantitative variables and as n(%) for qualitative variables unless otherwise specified. List of abbreviations: AKI, acute kidney injury; AST, aspartate transaminase; ALT, alanine transaminase; ALP, alkaline phosphatase; CTP, Child Turcotte Pugh; HBV, hepatitis B virus; HCV, hepatitis C virus; HE, hepatic encephalopathy; HVPG, hepatic venous pressure gradient; INR, international normalised ratio; MELD, model for end stage liver disease; NAFLD, non-alcoholic fatty liver disease; SBP, spontaneous bacterial peritonitis.